Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

 
You are here: Home / Protocols / Detection of Bladder CA by Microsatellite Analysis (MSA)

Detection of Bladder CA by Microsatellite Analysis (MSA)

108
Feng, Ziding — Fred Hutchinson Cancer Research Center

No involved investigator sites defined.

D4S243, D21S1245, FGA, D17S695, D16S476, D9S171, IFN-A, D20S48, D17S654, D16S310, THO1, D9SS162, D9S747, MBP and MBPA
Genomics
Prostate and Urologic Cancers Research Group
2

Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting bladder cancer in participants requiring cystoscopy. This technique will be compared to the diagnostic standard of cystoscopy, as well as to urine cytology. Goal 2: To determine the temporal performance characteristics of microsatellite analysis of urine sediment. Goal 3: To determine which of the 15 individual markers or combination of markers that make up the MSA test are most predictive of the presence of bladder cancer.

Aim 1: This study will test the specificity of MSA in two groups of participants without bladder cancer─both healthy, normal controls as well as participants without bladder cancer who have conditions known to confound the performance of previous urinary tests for bladder cancer. Aim 2: This study will test the sensitivity of MSA in the presence of clinically evident, pathologically confirmed bladder cancer. Aim 3: This study will test the sensitivity and specificity of MSA for the detection of bladder cancer among participants undergoing surveillance for bladder cancer. Aim 4: This study will test the value of MSA to predict subsequent development of bladder cancer among participants with a history of bladder cancer.
The “gold standard” in diagnosis and surveillance of bladder cancer is the macroscopic identification of disease during cystoscopy. Suspicious lesions are biopsied during cystoscopy, especially in participants with transitional cell carcinoma (TCC). The ideal test to replace cystoscopy or decrease the frequency of the surveillance cystoscopy in the management of bladder cancer would be technologically driven, highly sensitive, and rapid. Microsatellites are tandem repeat DNA sequences that are common, highly polymorphic genetic elements within the eukaryotic genome. Alterations, either expansion or deletions, of microsatellites were used as clonal markers for the detection of human cancer, including bladder cancer (Mao, Lee, Tockman, Erozan, Askin, & Sidransky, 1994).16 In preliminary studies, Mao et al., (1996)7 and Mourah et al., (1998)10 showed that microsatellite markers had high sensitivity and specificity in detecting bladder cancer in the voided urine specimens (Mao, Schoenberg, Scicchitano et al., 1996;7 Mourah, Cussenot, Vimont, et al., 1998).10 Further development of microsatellite testing to improve specificity, speed of testing, and operator efficiency may improve bladder cancer management. The microsatellite analysis described herein is based on Short Tandem Repeats (STR). The assay has been derived employing the STR technology. The STR allele designations and peak heights from the participant control sample (blood) are compared to the allele designations and peak heights from the participant urine sample. The purpose of the analysis is to identify loss of heterozygosity (LOH) and instability present in the urine sample.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 06/30/2017

The next EDRN Steering Committee Meeting is from September 12-14, 2017, in Seattle WA. Please click here to register and find out more information about the meeting.
Announcement



EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.